SARC Biannual Meeting
November 5, 2009
8:00 am - 12:00 pm
AGENDA

8:00 – 8:15  Welcome/SARC Update
Laurence Baker
Chair, SARC Board of Directors

8:15 – 9:20  Chawla/Rosenfeld Developmental Therapeutics Symposium
PET Evaluation of Sarcoma Treatment Response: “PERCIST” Criteria
Assessing Response in Sarcomas: Methods Are Clear; Results Are Murky
Richard Wahl
Scott Schuetze

9:20-9:35  Brief Update: Selected Ongoing and Recently Completed SARC Trials
Laurence Baker
- SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma
- SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP
- SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma
- SARC 007 Phase 2 Perifosine in chemoinsensitive sarcoma
- SARC 009 Phase 2 Dasatinib in metastatic sarcoma

9:35-9:50  Break

9:50-10:10 New Directions in Therapy for MPNST
Brigitte Widemann
- SARC 006 Phase 2 Sporadic vs. NF-associated MPNST
- SARC 016 Phase 2 RAD001 with and without bevacizumab in metastatic MPNST

10:10-10:30  Rationale and Study of IGF-1R in Ewing Sarcoma
Lee Helman
Alberto Pappo
Paul Meyers
- SARC011 Phase 2 IGF-1R in Ewing’s in selected sarcoma subtypes
- SARC013 Phase 3 Chemotherapy and R1507 or placebo in metastatic Ewing’s

10:30-10:50  Advancing Care of GIST Patients
George Demetri
Katie Janeway
Jonathan Trent
Suzanne George
- SARC 015 Phase 2 R1507 in wild-type GIST
- SARC 009 Phase 2 Dasatinib in metastatic GIST
- SARC 019 Phase 3 Imatinib PK testing in metastatic GIST

10:50-11:10  Src Kinase Inhibition of Osteosarcoma
Su Young Kim
- SARC 012 Phase 2 Sarcatinib in recurrent osteosarcoma/SARC009 Dasatinib in the osteosarcoma cohort

11:10-11:30  Collaboration with EORTC
Bihn Bui
- EORTC 62091/SARC020 Phase 2b EORTC study of ET743 in metastatic STS

11:30-12:00  Closed Session: SARC Business Update
(SARC Participants Only)